ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsqua...

Bibliografski detalji
Glavni autori:	Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators
Format:	Journal article
Jezik:	English
Izdano:	Wiley 2018

Slični predmeti

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
od: Morgensztern, D, i dr.
Izdano: (2017)

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
od: Morgensztern, D, i dr.
Izdano: (2018)

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
od: Talbot, D, i dr.
Izdano: (2018)

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
od: Govindan, R, i dr.
Izdano: (2017)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
od: Daniel Morgensztern, i dr.
Izdano: (2021-02-01)

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
od: Ponce Aix, S, i dr.
Izdano: (2020)

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
od: Corey J. Langer, i dr.
Izdano: (2018-07-01)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
od: Corey J. Langer, i dr.
Izdano: (2021-01-01)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
od: Eric Laille, i dr.
Izdano: (2015-01-01)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
od: Ajeet Gajra, i dr.
Izdano: (2018-07-01)

The uses of anxiety: Grace Abounding to the Chief of Sinners (1666)
od: Seymour, L
Izdano: (2023)

Short Toxin-like Proteins Abound in Cnidaria Genomes
od: Michal Linial, i dr.
Izdano: (2012-11-01)

Misperceptions of "light" cigarettes abound: National survey data
od: Thomson George, i dr.
Izdano: (2009-05-01)

Aboundance, Diversity and Distribution of Ichthyoplanktons in Creeks and Coastal Waters of Khouzestan Province
od: S. Dehghan; A. Savari; P. Kochenin; J. Ghafle marammazi
Izdano: (1999-01-01)

The Jurisdictional Basis, Elements and Remedies in the Action for Breach of Confidence - Uncertainty Abounds
od: Leo Tsaknis

Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.
od: Christine E Orr, i dr.
Izdano: (2022-01-01)

Improbabilities abound”: Daphne du Maurier’s Rule Britannia and the speculative political future
od: Aoife Byrne
Izdano: (2015-07-01)

Features of fibrosis regression abound in “non-cirrhotic” patients with resected hepatocellular carcinoma
od: Christine E. Orr, i dr.
Izdano: (2022-01-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
od: Véronique Hofman, MD, PhD, i dr.
Izdano: (2023-02-01)

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes
od: Garcia-Manero, G, i dr.
Izdano: (2021)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
od: Neda Stjepanovic, i dr.
Izdano: (2020-10-01)

Exodus, Psalms and Hebrews: A God abounding in steadfast love (Ex 34:6)
od: Alphonso Groenewald
Izdano: (2008-03-01)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
od: Jun Sugisaka, i dr.
Izdano: (2023-11-01)

Ticks and Tick-Borne Pathogens Abound in the Cattle Population of the Rabat-Sale Kenitra Region, Morocco
od: Latifa Elhachimi, i dr.
Izdano: (2021-12-01)

Soils rich in biological ice-nucleating particles abound in ice-nucleating macromolecules likely produced by fungi
od: F. Conen, i dr.
Izdano: (2018-07-01)

Length Frequency, Sex Ratio and Relative Aboundance (CPUE) of Astacus leptoductylus in Arass Reservior (1997-98)
od: M. Karimpor; N. Hosseinpor
Izdano: (1999-01-01)

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
od: Yoshimasa Shiraishi, i dr.
Izdano: (2022-09-01)

Computer processor unit 486
od: Universiti Teknologi Malaysia. Perpustakaan
Izdano: (1989)

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
od: Gridelli C, i dr.
Izdano: (2018-05-01)

Androgen Receptor Expression in Primary Nonsquamous Cell Rare-Variant Carcinomas of the Head and Neck
od: Siavash Rahimi MD, FRCPath, i dr.
Izdano: (2017-06-01)

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity
od: Hiroaki Ikawa, i dr.
Izdano: (2019-09-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
od: Daichi Fujimoto, MD, i dr.
Izdano: (2022-02-01)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
od: Hidetoshi Hayashi, i dr.
Izdano: (2011-01-01)

P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
od: Maria Amaya, i dr.
Izdano: (2023-08-01)

KIE 486 - KIMIA MAKANAN JUN 1994.
od: PPSK, Pusat Pengajian Sains Kimia
Izdano: (1994)

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
od: Shreya Bhatia, BS, i dr.
Izdano: (2024-11-01)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
od: Lisa M. Hess, PhD, i dr.
Izdano: (2022-06-01)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
od: Laurent Greillier, i dr.
Izdano: (2016-10-01)

An Epidemiologic study of Oral and Pharyngeal Nonsquamous Cell Malignant Tumors inKerman province, Iran
od: MR. Zarei, i dr.
Izdano: (2007-03-01)

Glenn's Suzuki one-cylinder repair and tune-up guide : models 50 cc, 55 cc, 80 cc, 90 cc, 120 cc, 125 cc, 185 cc, 250 cc, 400 cc/
od: 402466 Crawford, Charles W., i dr.
Izdano: (1972)